U.S. Capital Wealth Advisors LLC Grows Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

U.S. Capital Wealth Advisors LLC increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 314.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 83,070 shares of the biopharmaceutical company’s stock after purchasing an additional 63,009 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in Gilead Sciences were worth $6,730,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in GILD. OFI Invest Asset Management purchased a new stake in shares of Gilead Sciences in the 3rd quarter valued at $26,000. Tompkins Financial Corp boosted its stake in shares of Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 241 shares in the last quarter. Fortitude Family Office LLC purchased a new stake in Gilead Sciences during the 4th quarter valued at $29,000. Rakuten Securities Inc. purchased a new stake in Gilead Sciences during the 4th quarter valued at $33,000. Finally, Financial Connections Group Inc. purchased a new stake in Gilead Sciences during the 4th quarter valued at $40,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Down 0.8 %

Shares of Gilead Sciences stock traded down $0.55 during trading on Friday, hitting $64.78. The company’s stock had a trading volume of 7,822,720 shares, compared to its average volume of 7,345,331. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.72 and a current ratio of 0.98. The company has a fifty day simple moving average of $70.55 and a two-hundred day simple moving average of $75.83. The company has a market capitalization of $80.66 billion, a PE ratio of 179.94, a P/E/G ratio of 1.30 and a beta of 0.22. Gilead Sciences, Inc. has a 52 week low of $64.33 and a 52 week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.49) by $0.17. The company had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. Gilead Sciences’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period last year, the business earned $1.37 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 3.74 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 4.75%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

Wall Street Analyst Weigh In

GILD has been the subject of several analyst reports. Morgan Stanley dropped their price target on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th. Truist Financial cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and dropped their price target for the company from $91.00 to $82.00 in a research report on Thursday, February 22nd. Oppenheimer reissued an “outperform” rating and set a $105.00 price target on shares of Gilead Sciences in a research report on Friday, April 19th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 26th. Finally, TD Cowen dropped their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Friday, April 26th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Gilead Sciences currently has an average rating of “Hold” and an average price target of $83.69.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.